NCT05008913 (ADME) is a Phase 1 clinical trial of [14C]Adavosertib in Advanced Solid Tumors, sponsored by AstraZeneca.

Who is sponsoring NCT05008913?

NCT05008913 is sponsored by AstraZeneca.

What drugs are being tested in NCT05008913?

Interventions in NCT05008913: [14C]Adavosertib.

What condition does NCT05008913 study?

NCT05008913 studies Advanced Solid Tumors.

Is NCT05008913 still recruiting?

NCT05008913 is currently terminated. Last updated 6 September 2022.

Last reviewed 2022-09-06 · How we verify

NCT05008913: ADME

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

Terminated Phase 1 Last updated 6 September 2022

What this trial tests

Phase 1 trial testing [14C]Adavosertib in Advanced Solid Tumors in 2 participants. Terminated before completion.

Timeline

1 October 2021

Primary endpoint
16 November 2021

16 November 2021

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	other
Enrollment	2
Start date	1 October 2021
Primary completion	16 November 2021
Estimated completion	16 November 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

[14C]Adavosertib — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-randomised study in patients with advanced solid malignancies

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders.
Alli VJ, Yadav P, Suresh V, Jadav SS. · · 2023 · cited 18× · PMID 37323408 · DOI 10.1021/acsomega.3c01558
Targeting the DNA damage response in cancer.
Federica G, Michela C, Giovanna D. · · 2024 · cited 12× · PMID 39492835 · DOI 10.1002/mco2.788
Human Absorption, Metabolism, and Excretion (hAME) Mass Balance Studies in Patients With Cancer.
Heras BL, Oelke C, Atwell P, Herrero H, et al · · 2026 · PMID 42212929 · DOI 10.1111/cts.70620

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05008913 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 6 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05008913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing